Here are five things to know:
1. The device will be commercially available in mid-September this year.
2. The system will include the second generation instrument to improve patient safety and surgeon ease of use.
3. The Valeo LL is made of a micro composite silicon nitride biomaterial designed for bone growth and osteointegration. The device also contains anti-infective properties and is semi-radiolucent.
4. The system has clearly visible boundaries in X-rays and doesn’t produce artifacts under MRI or CT scans.
5. The device is indicated for intervertebral body fusion for skeletally mature patients and designed for use with autograft to facilitate fusion.
“Initial feedback from our beta users has been positive and we are very pleased to offer this lateral interbody fusion device system which provides surgeons additional procedure options and allows Amedica access to one of the fastest growing segments in the lumbar fusion market,” says Sonny Bal, MD, chairman and CEO of Amedica.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
